U.S. markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.92 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.91 (-0.21%)
     
  • Crude Oil

    83.98
    +1.48 (+1.79%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • Silver

    24.39
    +0.22 (+0.91%)
     
  • EUR/USD

    1.1646
    +0.0015 (+0.13%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • GBP/USD

    1.3761
    -0.0034 (-0.25%)
     
  • USD/JPY

    113.5200
    -0.4680 (-0.41%)
     
  • BTC-USD

    60,482.32
    -595.58 (-0.98%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.25 (+0.34%)
     

Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Eli Lilly And Co's (NYSE: LLY) lebrikizumab ADvocate 1 and ADvocate 2 Phase 3 clinical trials met primary and all key secondary endpoints at Week 16.

  • Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis (AD) in the two Phase 3 trials.

  • Results demonstrated that more than half of the patients achieved at least 75% clearance to total clearance on lebrikizumab monotherapy.

  • Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, has a long half-life, and blocks IL-13 signaling.

  • The FDA has granted Fast Track designation to lebrikizumab.

  • The full study results from ADvocate 1 and ADvocate 2 will be disclosed at future congresses in 2022.

  • The most common adverse events included conjunctivitis, nasopharyngitis, and headache for lebrikizumab-treated patients.

  • Discontinuations due to adverse events were similar in the lebrikizumab group (1.4%) compared to placebo (1.7%).

  • Price Action: LLY shares closed at $264.21 on Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.